Equities

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.82
  • Today's Change-0.37 / -4.52%
  • Shares traded1.70m
  • 1 Year change+57.03%
  • Beta1.8164
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform8
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for BioCryst Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 30.00 and a low estimate of 8.00. The median estimate represents a 40.66% increase from the last price of 7.82.
High283.6%30.00
Med40.7%11.00
Low2.3%8.00

Earnings history & estimates in USD

On Nov 04, 2024, BioCryst Pharmaceuticals Inc reported 3rd quarter 2024 losses of -0.07 per share. This result was in line with the consensus of the 9 analysts following the company and exceeded last year's 3rd quarter results by 63.16%.
The next earnings announcement is expected on Feb 24, 2025.
Average growth rate+7.51%
BioCryst Pharmaceuticals Inc reported annual 2023 losses of -1.18 per share on Feb 26, 2024.
Average growth rate-7.08%
More ▼

Revenue history & estimates in USD

BioCryst Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 117.09m. This bettered the 112.50m consensus of the 8 analysts covering the company. This was 70.24% above the prior year's 3rd quarter results.
Average growth rate+7.99%
BioCryst Pharmaceuticals, Inc. had revenues for the full year 2023 of 331.41m. This was 22.37% above the prior year's results.
Average growth rate+203.39%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.